Recent Quotes (30 days)

You have no recent quotes
chg | %

Biosyent Inc.  

(Public, CVE:RX)   Watch this stock  
Find more results for RX
7.00
+0.12 (1.74%)
Delayed:   10:27AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.85 - 7.00
52 week 5.91 - 12.82
Open 6.85
Vol / Avg. 1,751.00/26,094.00
Mkt cap 97.55M
P/E 28.11
Div/yield     -
EPS 0.25
Shares 13.94M
Beta 0.69
Inst. own     -
Aug 12, 2015
Q2 2015 Biosyent Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 23.68% 25.83%
Operating margin 32.97% 33.56%
EBITD margin - 33.94%
Return on average assets 29.93% 37.69%
Return on average equity 35.41% 48.47%
CDP Score - -

Address

Suite 520, 170 Attwell Dr.
TORONTO, ON M9W 5Z5
Canada
+1-905-2060013 (Phone)
+1-905-2061413 (Fax)

Website links

Description

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., sources, acquires or in-licenses pharmaceutical products and markets these products in Canada. Through its subsidiary, Hedley Technologies Ltd., the Company also operates legacy business marketing bio and non-chemical insecticides. Its products include FeraMAX 150, Cathejell, FeraMAX Powder, RepaGyn, Proktis-M and Aguettant System. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia (IDA). Cathejell is indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations and other endourethral operations; endoscopies, proctoscopies, rectoscopies, and tracheal intubations. RepaGyn is a vaginal suppository, which helps relieve dryness and helps to promote healing of vaginal mucosa. Proktis-M rectal suppository is designed to help healing of the anus and rectum.

Officers and directors

Rene C. Goehrum Chairman of the Board, President, Chief Executive Officer
Alfred D'Souza Chief Financial Officer
Kevin Wilson Vice President - Sales and Marketing of BioSyent Pharma Inc
Douglas R. Larson Secretary, Director
Peter D. Lockhard Independent Director
Paul R. Montador Independent Director
Milton E. Wakefield Independent Director
Stephen Wilton Independent Director